HomeCompareHLOC vs PFE

HLOC vs PFE: Dividend Comparison 2026

HLOC yields 425.53% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLOC wins by $18058.55M in total portfolio value
10 years
HLOC
HLOC
● Live price
425.53%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18058.60M
Annual income
$12,349,610,253.13
Full HLOC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — HLOC vs PFE

📍 HLOC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLOCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLOC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLOC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLOC
Annual income on $10K today (after 15% tax)
$36,170.21/yr
After 10yr DRIP, annual income (after tax)
$10,497,168,715.16/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, HLOC beats the other by $10,497,146,395.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLOC + PFE for your $10,000?

HLOC: 50%PFE: 50%
100% PFE50/50100% HLOC
Portfolio after 10yr
$9029.32M
Annual income
$6,174,818,255.92/yr
Blended yield
68.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HLOC
No analyst data
Altman Z
10.0
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLOC buys
0
PFE buys
0
No recent congressional trades found for HLOC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLOCPFE
Forward yield425.53%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$18058.60M$49.6K
Annual income after 10y$12,349,610,253.13$26,258.71
Total dividends collected$17541.95M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HLOC vs PFE ($10,000, DRIP)

YearHLOC PortfolioHLOC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$53,253$42,553.19$9,153$693.39+$44.1KHLOC
2$268,765$211,784.42$8,593$849.25+$260.2KHLOC
3$1,286,515$998,936.38$8,336$1,066.78+$1.28MHLOC
4$5,845,421$4,468,849.76$8,437$1,384.80+$5.84MHLOC
5$25,230,957$18,976,356.52$9,013$1,875.40+$25.22MHLOC
6$103,547,438$76,550,313.71$10,306$2,680.72+$103.54MHLOC
7$404,404,397$293,608,638.27$12,820$4,101.38+$404.39MHLOC
8$1,504,383,912$1,071,671,207.21$17,673$6,826.70+$1504.37MHLOC
9$5,335,499,864$3,725,809,078.26$27,543$12,591.86+$5335.47MHLOC
10$18,058,595,107$12,349,610,253.13$49,560$26,258.71+$18058.55MHLOC

HLOC vs PFE: Complete Analysis 2026

HLOCStock

Helo Corp., a wellness technology company, provides wearable devices for use in the quantified-self wellness market. The company's wearable devices and related applications offer its end-users with health-related knowledge acquired through self-tracking. It offers VYYO Vista, which captures data that can be used to analyze resting and exercising heart rates, blood pressure estimation, breath rate, and energy levels, as well as provide insights into mood and sleep; and VYVO Sense, a smartband with 6 axes movement detection and an electrocardiogram (ECG) sensor. The company also provides VYVO Icon, a smartwatch that enables data to be collected to allow third parties to deduce parameters, such as body fat percentage, visceral fat levels, muscle, and bone mass; gather data to generate a third-party representation of an ECG; and provide continuous detection of possible irregular heartbeats comprising an atrial fibrillation or other arrhythmias. In addition, it offers VYVO Leggera, a smart weighing scale that can measure body weight, and has a BI sensor to capture data used to deduce bone weight, visceral fat, and body mass index; VYVO Vista+; and VYVO Watch Lite, which has data collection capabilities that enable features, including continuous atrial fibrillation detection, mood, and energy monitoring, as well as fall detection, SpO2 measurement capability, and sleep apnea detection. Further, it provides VYVO Watch Lite SE, which offers a body temperature result with an accuracy of up to ±0.1°C; and VYVO Watch Generation 2, a watch that enables medical-grade measurements with enhanced data accuracy for blood oxygen measurements, vascular aging, and ECGs. Helo Corp. sells its products through its marketing and distribution partner, VYVO HK Ltd., and its distribution network. The company was formerly known as World Technology Corp. and changed its name to Helo Corp. in October 2018. Helo Corp. was incorporated in 2010 and is headquartered in San Francisco, California.

Full HLOC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HLOC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLOC vs SCHDHLOC vs JEPIHLOC vs OHLOC vs KOHLOC vs MAINHLOC vs JNJHLOC vs MRKHLOC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.